These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 19877737)

  • 1. Invasive fungal infections: the challenge continues.
    Gullo A
    Drugs; 2009; 69 Suppl 1():65-73. PubMed ID: 19877737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients at high risk of invasive fungal infections: when and how to treat.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anidulafungin, a new echinocandin: effectiveness and tolerability.
    Menichetti F
    Drugs; 2009; 69 Suppl 1():95-7. PubMed ID: 19877741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echinocandins in the management of invasive fungal infections, Part 2.
    Morris MI; Villmann M
    Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin--state of affairs from a clinical perspective.
    Vehreschild JJ; Kümmerle T; Karthaus M; Cornely OA
    Mycoses; 2007; 50 Suppl 1():38-43. PubMed ID: 17394608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging echinocandins for treatment of invasive fungal infections.
    Turner MS; Drew RH; Perfect JR
    Expert Opin Emerg Drugs; 2006 May; 11(2):231-50. PubMed ID: 16634699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bench-to-bedside review: Candida infections in the intensive care unit.
    Méan M; Marchetti O; Calandra T
    Crit Care; 2008; 12(1):204. PubMed ID: 18279532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of properties and clinical efficacy of the echinocandins.
    Kim R; Khachikian D; Reboli AC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Micafungin: experimental therapy of fungal infections in animal models].
    Javier Pastor F; Guarro J
    Rev Iberoam Micol; 2009 Mar; 26(1):42-8. PubMed ID: 19463276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echinocandins: The Expanding Antifungal Armamentarium.
    Aguilar-Zapata D; Petraitiene R; Petraitis V
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
    Kuti EL; Kuti JL
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1287-300. PubMed ID: 20822479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antifungal agents.
    Gupta AK; Tomas E
    Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for isolation of fluconazole and echinocandin non-susceptible
    Papadimitriou-Olivgeris M; Spiliopoulou A; Fligou F; Tsiata E; Kolonitsiou F; Nikolopoulou A; Papamichail C; Spiliopoulou I; Marangos M; Christofidou M
    J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34431765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.